Severe asthma: An update for 2019

Research output: Contribution to specialist publicationArticle

1 Scopus citations

Abstract

Asthma is a common respiratory disorder, and the presentation of patients with acute, poorly controlled asthma remains a clinical challenge. In current guidelines, severe asthma represents a subset of difficult-to-treat asthma that, despite treatment of contributing factors and patient compliance with optimized therapy, remains uncontrolled, or asthma that worsens when high-intensity therapy is decreased. Acute exacerbations are managed with inhaled bronchodilators, inhaled corticosteroids, and oral corticosteroids. Patient-specific pharmacotherapy to prevent acute exacerbations includes the use of inhaled corticosteroids plus a long-acting bronchodilator, a short-acting bronchodilator for rescue, a long-acting muscarinic, a leukotriene antagonist, and biologics.

Original languageEnglish (US)
PagesHS2-HS7
Volume44
No7
Specialist publicationU.S. Pharmacist
StatePublished - 2019

All Science Journal Classification (ASJC) codes

  • Pharmacy
  • Pharmacology
  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Severe asthma: An update for 2019'. Together they form a unique fingerprint.

Cite this